ECSP13012461A - Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor - Google Patents

Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Info

Publication number
ECSP13012461A
ECSP13012461A ECSP13012461A ECSP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A EC SP13012461 A ECSP13012461 A EC SP13012461A
Authority
EC
Ecuador
Prior art keywords
detect
tor
activity
quinasa
measure inhibition
Prior art date
Application number
Other languages
English (en)
Inventor
Suichan Xu
Lilly Wong
jian hua Ding
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of ECSP13012461A publication Critical patent/ECSP13012461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Proporcionados en la presente se encuentran métodos para detectar y/o medir la inhibición de la actividad quinasa TOR en un sujeto y usos asociados con la misma.
ECSP13012461 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor ECSP13012461A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36945510P 2010-07-30 2010-07-30

Publications (1)

Publication Number Publication Date
ECSP13012461A true ECSP13012461A (es) 2013-03-28

Family

ID=45527332

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012461 ECSP13012461A (es) 2010-07-30 2013-02-26 Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor

Country Status (22)

Country Link
US (1) US20120028972A1 (es)
EP (1) EP2598885B1 (es)
JP (1) JP2013535684A (es)
KR (1) KR20130136970A (es)
CN (1) CN103119445B (es)
AU (1) AU2011282553B2 (es)
BR (1) BR112013002279A2 (es)
CA (1) CA2807147A1 (es)
CO (1) CO6680668A2 (es)
CR (1) CR20130070A (es)
EC (1) ECSP13012461A (es)
ES (1) ES2591135T3 (es)
MX (1) MX337907B (es)
MY (1) MY170983A (es)
NI (1) NI201300013A (es)
NZ (1) NZ606495A (es)
PH (1) PH12013500240A1 (es)
RU (1) RU2587040C2 (es)
SG (1) SG187659A1 (es)
UA (1) UA111724C2 (es)
WO (1) WO2012016113A1 (es)
ZA (1) ZA201300921B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
KR101978537B1 (ko) * 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
WO2013138557A1 (en) * 2012-03-15 2013-09-19 Signal Pharmaceuticals, Llc Treatment of cancer with tor kinase inhibitors
AU2013203714B2 (en) * 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
MX2015009209A (es) 2013-01-16 2016-03-17 Signal Pharm Llc Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos.
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
US9505764B2 (en) * 2013-04-17 2016-11-29 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP2986318A1 (en) * 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
CA2908957C (en) * 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2908353C (en) * 2013-04-17 2021-11-02 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MX368286B (es) * 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
AU2014254059B2 (en) * 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a TOR kinase inhibitor and a cytidine analog for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3，4-二氢吡嗪并[2，3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
ES2959860T3 (es) 2017-06-22 2024-02-28 Celgene Corp Tratamiento del carcinoma hepatocelular caracterizado por la infección por el virus de la hepatitis B

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135298B2 (en) * 2003-03-26 2006-11-14 The Burnham Institute For Medical Research Screening assay for agents that alter target of Rapamycin activity
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY OF SENSITIVITY OF A TUMOR AGAINST A MTOR INHIBITOR
GB0509748D0 (en) * 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7981893B2 (en) * 2006-10-19 2011-07-19 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway

Also Published As

Publication number Publication date
SG187659A1 (en) 2013-03-28
RU2587040C2 (ru) 2016-06-10
JP2013535684A (ja) 2013-09-12
CO6680668A2 (es) 2013-05-31
CN103119445A (zh) 2013-05-22
CR20130070A (es) 2013-05-20
PH12013500240A1 (en) 2013-04-01
MY170983A (en) 2019-09-23
ZA201300921B (en) 2014-04-30
US20120028972A1 (en) 2012-02-02
AU2011282553B2 (en) 2015-04-02
NI201300013A (es) 2013-04-19
CA2807147A1 (en) 2012-02-02
BR112013002279A2 (pt) 2018-04-24
NZ606495A (en) 2014-08-29
ES2591135T3 (es) 2016-11-25
EP2598885B1 (en) 2016-07-20
KR20130136970A (ko) 2013-12-13
EP2598885A4 (en) 2014-03-26
MX337907B (es) 2016-03-28
UA111724C2 (uk) 2016-06-10
RU2013108840A (ru) 2014-09-10
AU2011282553A1 (en) 2013-03-14
EP2598885A1 (en) 2013-06-05
MX2013001293A (es) 2013-04-29
WO2012016113A1 (en) 2012-02-02
CN103119445B (zh) 2015-10-21

Similar Documents

Publication Publication Date Title
CR20130070A (es) Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor
IL264770B (en) Diagnostic assays and kits for detection of folate receptor 1
IL288009A (en) Use of inhibitors of bruton's tyrosine kinase (btk)
CO6801640A2 (es) Ensayos interrogatorios basados en células y usos de los mismos
PL2826161T3 (pl) Łączenie pomiarów jakości kanału w oparciu o sygnały odniesienia sondowania i sygnały odniesienia demodulacji
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
ME03063B (me) Supstituisani 3-haloalilamin inhibitori ssao i njihove primene
BR112013030095A2 (pt) inibidores de atividade de lrrk2 cinase
BR112015001087A2 (pt) métodos para detectar e medir agregação
IL227952A0 (en) Method of diagnosing cancer and diagnosis kit using measurement of nk activity
SG11201406561XA (en) Test probe assembly and related methods
HK1213046A1 (zh) 動態bh3分析
IL229357B (en) Using location and force measurements to estimate tissue thickness
BR112015002289A2 (pt) aptâmeros cd133 para a detecção de células tronco cancerosas
PT2751279T (pt) Métodos e composições para detetar o nível de atividade de exocitose lisossomal e métodos de utilização
DK2659071T6 (da) Falsk skillevæg med tredobbelt tykkelse
EP2810828A4 (en) SIGNIERPLATTE
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
EP2849743A4 (en) CANCER CELL INHIBITING MEDICINE AND CANCER STEM CELL DETECTION PROBE
EP2849752A4 (en) CANCER CELL INHIBITING MEDICINE AND CANCER STEM CELL DETECTION PROBE
ES1072702Y (es) Tapon roscado
DK2739748T3 (da) Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
HUE050713T2 (hu) Módszerek az ALFA-4 integrin aktivitás eltéréseinek meghatározásához, a sVCAM ÉS/VAGY sMAdCAM szintek egymáshoz viszonyításával
EP2836610A4 (en) METHOD FOR MEASURING POLYMERASE ACTIVITY, USEFUL FOR SENSITIVE QUANTITATIVE MEASUREMENTS OF ANY POLYMERASE EXTENSION ACTIVITIES AND FOR DETERMINING THE PRESENCE OF LIVABLE CELLS
HRP20181744T1 (hr) Komplet za pronalaženje, praćenje i određivanje gvhd